{
  "docId": "019de076-883a-72e4-86fb-18270cd4f977",
  "docSlug": "5c729b46407684473082dcb9c39fe3fc",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 25,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "Clinical trial identifier NCT05873686 is provided.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/22",
  "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
  "deckJsonHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977.json",
  "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.033,
        "w": 0.346,
        "x": 0.047,
        "y": 0.141
      },
      "kind": "paragraph",
      "text": "Patients with advanced solid tumors",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f3d1ba0-b588-4b02-ac7c-9a55a83f20a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.026,
        "w": 0.339,
        "x": 0.33,
        "y": 0.237
      },
      "kind": "source-note",
      "text": "Clinicaltrials.gov NCT05873686",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e57d4f2-31a1-45bd-aaa3-eb3c73d9dd11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.488,
        "w": 0.52,
        "x": 0.24,
        "y": 0.289
      },
      "kind": "table",
      "text": "Phase 1a Dose Escalation Starting dose of 20 mg, QD Primary Objective: Select doses/schedules for Phase 1b Key Endpoints: Assess Pharmacokinetics, pharmacodynamics, lab abnormalities, dose limiting toxicities",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25e97cf2-ac4a-4205-9b1e-68590bf10fe1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.696,
        "x": 0.047,
        "y": 0.065
      },
      "kind": "title",
      "text": "NXP900: Phase 1a Initiated in 3Q2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "318809d2-49cc-4f0d-adad-d2f5ea31a733",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "8bbacf33-3672-4af4-82ac-b8ca3783072b",
      "evidence": "The slide provides an update on the Phase 1a initiation of NXP900.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 22,
      "from": 13,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
      "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
      "position": 1,
      "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}